Browse drugs

…city, with G3/4 events reported in 22% compared with 14% in the nivolumab monotherapy arm. An update presented at the European Society of…

…e completed successfully. Forty-one patients with rGBM received bevacizumab-SIACI, 7 with ndGBM bevacizumab-SIACI, and 22 with ndGBM cetuximab-SI…

…C), platinum rechallenge retains activity in selected patients. Bevacizumab with chemotherapy improves PFS without OS benefit. Novel antibo…

…cyte count (ALC) identifies a subgroup unlikely to benefit from pembrolizumab.Methods We performed a single-center retrospective study of adu…

…with PD-L1 blockade. The EORTC-1508GCG phase II trial evaluated atezolizumab (anti-PD-L1), bevacizumab (anti-VEGF), and low-dose aspirin in …

….5 months), all of whom received platinum-based chemotherapy (± bevacizumab) in first- or second-line settings; 86 patients also received c…

…im T-Y, Tai WMD, Kang Y-K, Lau G, et al. Safety and efficacy of durvalumab plus bevacizumab in unresectable hepatocellular carcinoma: resu…

… with its inherent morbidity of diminished vision. She received Bevacizumab (an anti-angiogenic agent; an anti-VEGF-A agent) with which she…

… therapy with atezolizumab, an immune checkpoint inhibitor, and bevacizumab, a vascular endothelial growth factor (VEGF) inhibitor. Three d…

…atients, with durable responses to combination regimens such as atezolizumab plus bevacizumab occurring in a minority.1 2 Neutrophils, long …

…immune checkpoint blockade (ICB). Since the landmark success of atezolizumab plus bevacizumab in the IMbrave150 trial, immunotherapy has bec…

…ed clinical outcomes in an external patient cohort treated with atezolizumab plus bevacizumab.Conclusions These findings establish PDOTS as …